Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
4
×
national top stories
roche
boston
boston blog main
boston top stories
clinical trials
deals
fda
europe top stories
genentech
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceuticals
avapritinib
billy dunn
biogen
biopharma
blueprint medicines
boehringer ingelheim
cstone pharmaceuticals
dicerna pharamceuticals
drug prices
drug pricing
duchenne
eli lilly
europe blog main
european medicines agency
evrysdi
fisogatinib
flatiron health
gene therapy
hepatitis b
hepatitis b virus
hepatocellular carcinoma
hereditary transthyretin amyloidosis
investing
ionis pharmaceuticals
What
roche
4
×
drug
fda
approval
gene
intended
medicine
medicines
team
therapy
approved
atrophy
betting
billion
biopharma
blueprint
cancer
candidate
caught
causing
currently
daily
deal
dicerna
disease
duchenne
evrysdi
eye
friday
green
hepatitis
historic
home
lights
liquid
marketing
muscle
muscular
new
oral
Language
unset
4
×
Current search:
roche
×
unset
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug